Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.42 |
| ▸ | NPC1 | O15118 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6099357 | 1.00 | RAB9A (0.42) | RAB9ANPC1MAPTPOLBSMN1; SMN2 | |
| SCHEMBL27514889 | 0.90 | FPR1 (0.45) | RAB9ANPC1MAPTPOLBSMN1; SMN2 | |
| SCHEMBL7674137 | 0.89 | RAB9A (0.43) | RAB9ANPC1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL7674142 | 0.89 | RAB9A (0.43) | RAB9ANPC1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL3727512 | 0.86 | TMPRSS4 (0.39) | MEN1KMT2A | |
| SCHEMBL6112389 | 0.86 | TMPRSS4 (0.39) | MEN1KMT2A | |
| SCHEMBL3732549 | 0.86 | TMPRSS4 (0.39) | MEN1KMT2A | |
| SCHEMBL30042804 | 0.86 | TMPRSS4 (0.39) | MEN1KMT2A | |
| SCHEMBL30421510 | 0.85 | TMPRSS4 (0.39) | MEN1KMT2A | |
| SCHEMBL6102018 | 0.83 | KDM4E (0.36) | RAB9ANPC1MAPTPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148243-B2 | Antivirals | MEDIVIR AB (SE) | 2006-12-12 | — | — | US | disclosed |
| EP-1054867-B1 | ANTIVIRALS | MEDIVIR AB (SE) | 2004-04-14 | — | — | EP | disclosed |
| US-20030119881-A1 | N-((2-hydroxy,3-(alkyloxo),6-halophenyl)-(1,2-cyclopropylene) -),N'-((5-cyano or bromo)pyrid-2-yl)urea; retroviricides; HIV reverse transcriptase inhibitors; prolonged time to virus resistance | MEDIVIR AB (SE) | 2003-06-26 | — | — | US | disclosed |
| US-6486183-B1 | Antivirals | MEDIVIR AB (SE) | 2002-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119881-A1 | N-((2-hydroxy,3-(alkyloxo),6-halophenyl)-(1,2-cyclopropylene) -),N'-((5-cyano or bromo)pyrid-2-yl)urea; retroviricides; HIV reverse transcriptase inhibitors; prolonged time to virus resistance | RAD1, POLL, PNPO | RAB9A 2922/4885NPC1 550/4885MAPT 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.